ANI Pharmaceuticals has chosen its new president and CEO to replace interim chief Patrick Walsh who stepped in after the departure Arthur Przybyl earlier this year. Meanwhile, key personnel announcements have also been made by Teva and Mylan.

Novavax has granted Serum Institute rights to develop, manufacture and commercialize its COVID-19 vaccine candidate in selected regions, in another endorsement of the Indian group's capabilities. The agreement, which expands on an earlier association, gives Serum exclusive marketing rights in India until the deal ends and non-exclusive rights for developing countries to the end of the pandemic, with the US firm getting half of net revenue.

The study is designed to support the regulatory approval process in China and confirm that the safety and immunogenicity profile observed in German and US trials is comparable to that of Chinese participants, according to BioNTech.

A first look at the clinical data for Novavax’s COVID-19 vaccine suggests it can produce strong antibody responses while being well tolerated.